Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etravirine PK and Safety with Atazanavir/Ritonavir in Treatment-Experienced HIV-1
NCT00896051Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2009
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of etravirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration of Atazanavir at Week 2, Minimum Plasma Concentration of Atazanavir at Week 2 and 6 more. Started Aug 2009; status: completed.
02
Drugs
etravirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00896051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00896051.